COMMENTARY: Mortality rate from early prostate cancer increased 3-fold after 15 years following the diagnosis
- Intermittent ADT may benefit men with advanced PCa. Sieve, Vonne // Urology Times;4/1/2006, Vol. 34 Issue 4, p16
The article reveals that intermittent androgen suppression is beneficial in select men with advanced prostate cancer. Intermittent therapy is generally defined as administration of total androgenic blockade until the prostate-specific antigen falls to zero or near zero. The article discusses...
- UtilitÃ della linfoadenectomia pelvica nel carcinoma prostatico con PSA <10 ng/ml. BERARDI, B.; PICCINNI, R.; CAFARELLI, A.; CALLEA, A.; TEMPESTA, A.; GALA, F.; ZIZZI, V.; SBLENDORIO, D.; CRUDELE, G.; TRAFICANTE, A. // Urologia;2009 Supplement, Vol. 76 Issue S-12, pS41
Radical prostatectomy is the best treatment for patients with T1-2 prostate cancer and a life expectancy of over 10 years, but no pN1 patient that underwent only surgery, was progression free at 10 years (Partin 1994). In the last 10 years we performed 441 consecutive pelvic lymphadenectomy in...
- Screening for Prostate Cancer Risk: Fantasy or Reality. Batra, Jyotsna; Yousef, George M. // Canadian Journal of Pathology;Winter2015, Vol. 7 Issue 4, p4
No abstract available.
- Data Support Intermittent Androgen Suppression. // Renal & Urology News;Apr2011, Vol. 10 Issue 4, p24
The article reports on the outcomes associated with intermittent androgen suppression (IAS) and continuous androgen deprivation (CAD) when applied to men who have prostate-specific antigen (PSA) progression after radiotherapy for prostate cancer (PCa).
- RP has edge over radiotherapy in low-risk patients. Guttman, Cheryl // Urology Times;Sep2002, Vol. 30 Issue 9, p13
Compares the efficacy of radical prostatectomy versus external beam radiation therapy for treating clinically localized prostate cancer diagnosed during prostate-specific antigen (PSA) screening. Survival rate; Radiation dose; Link of radiation dose and PSA outcome.
- Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). // Current Medical Literature: Urology;2008, Vol. 14 Issue 3, p65
The article discusses research on the use of prostate-specific antigen (PSA) level to guide the optimum timing of androgen-deprivation therapy (ADT) in prostate cancer. It references a study by U. E. Studer et al, published in volume 53 of "European Urology." They found that patients with a PSA...
- Prostate Cancer and Pomegranate Juice. Finkel, Jon // Life Extension;Oct2009, Vol. 15 Issue 10, p1
The article presents findings of a study which examines the effect of pomegranate juice on men who underwent radiation therapy or surgery for prostate cancer in the U.S. The study revealed that lower prostate-specific antigen (PSA) levels were found in men who take eight ounces of pomegranate...
- Does the Benefit Justify the Risk? Albertsen, Peter C. // JNCI: Journal of the National Cancer Institute;1/6/2010, Vol. 102 Issue 1, p4
The article discusses various issues concerning the clinical use and adverse outcomes of androgen deprivation therapy (ADT). A brief historical perspective on prostate-specific antigen (PSA) and ADT is presented. The adverse outcomes of ADT are described, including its negative effect on quality...
- CD10 and Endothelin-1 are Inversely Expressed in Early Prostate Cancer and Predict PSA Failure after Radical Prostatectomy. Vlachostergios, Panagiotis J.; Karasavvidou, Foteini; Kakkas, Grigorios; Moutzouris, George; Patrikidou, Anna; Voutsadakis, Ioannis A.; Kapatou, Kassiani; Daliani, Danai D.; Melekos, Michael D.; Papandreou, Christos N. // Journal of Cancer Science & Therapy;2011 Supplement 1, Vol. 3, p1
Background: Loss of the membrane endopeptidase CD10 plays an important role in the development of neuropeptide-mediated androgen-independent prostate cancer cell growth. The aim of this study was to investigate the potential prognostic value of the CD10/neuropeptide axis with regard to...